Krka has announced the launch of Flovuxin, a fast-acting acting, injectable solution for bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Mycoplasma bovis and Histophilus somni, associated with pyrexia.
Flovuxin is a combined formulation of florfenicol and flunixin, which delivers effective treatment for bovine respiratory infections via a single dose.
Manufactured by Krka at its European production plant, Flovuxin offers treatment efficacy combined with improved value to vet practices and convenience on farm.
Krka’s Farm key account manager Charlotte Read highlights: “BRD remains a priority issue on farm and advising farmers on the management of BRD risks, and treatment options when needed, is a key task for farm vets.
Flovuxin’s combined formulation is a high efficacy BRD treatment acting within six hours, to improve treatment outcomes.”
Will Ridgway, UK national sales manager, adds: “The Krka sales team is delighted to bring farm vets this new addition to our BRD treatment range, which already includes Fenflor and Tuloxxin.
“The Flovuxin launch is further confirmation of Krka’s commitment to work with vets and farmers to understand the everyday challenges they face and to provide effective, flexible and affordable solutions.”
Krka UK is the fastest growing animal health company in the United Kingdom and is a subsidiary of Slovenia-based Krka, d. d. Novo Mesto, a world leader in generic pharmaceuticals for both human and animal health.
Working closely with customers, Krka supplies licensed medicines that deliver effective and consistent performance in clinical practice.
Krka’s Animal Health Portfolio provides high efficacy pharmaceuticals for both companion and food producing animals covering parasite control, antibiotics and pain relief.
Key brands include Milprazon chewable and Prinocate, for parasite management in cats and dogs, and Tolracol for coccidiosis prevention on farm.
